

**NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE**

**GUIDANCE EXECUTIVE (GE)**

**Consideration of consultation responses on review proposal**

**Review of TA121 Carmustine implants and temozolomide for the treatment of newly diagnosed high grade glioma**

This guidance was issued June 2007 with a review date of August 2010

Background

At the GE meeting on 03 August 2010, it was agreed we would consult on the review plans for this guidance. A four week consultation has been conducted with consultees and commentators and the responses are presented below.

<b>Proposal put to consultees:</b>	The decision to review the guidance should be deferred until 2015. That we consult on the proposal.
------------------------------------	---

GE is asked to consider the original proposal in the light of the comments received from consultees and commentators, together with any responses from the appraisal team. It is asked to agree on the final course of action for the review.

<b>Recommendation post consultation:</b>	The decision to review the guidance should be deferred until 2015.
--	--

<b>Respondent</b>	<b>Response to proposal</b>	<b>Details</b>	<b>Comment from Technology Appraisal</b>
Association of British Neurologists	Agree		Comment noted
British Association of Surgical Oncology	No comment		Comment noted
Bristol Myers Squibb Pharmaceuticals	Agree		Comment noted
Merck Sharp & Dohme Limited	Agree		Comment noted
Royal College of Nursing	Agree		Comment noted
National Cancer Research Institute Royal College of Physicians Royal College of Radiologists Association of Cancer Physicians Joint Collegiate Committee for Oncology	Agree		Comment noted
Welsh Assembly Government	No comment		Comment noted

**No response received from:**

<b>Consultees</b>	<b>Commentators (no right to submit or appeal)</b>
<p><u>Manufacturers/sponsors</u></p> <ul style="list-style-type: none"> <li>• Archimedes Pharma UK (carmustine implants)</li> <li>• Hexal (temozolomide)</li> <li>• Hospira (temozolomide)</li> <li>• Medac UK (temozolomide)</li> <li>• Schering Plough (temozolomide)</li> <li>• Teva UK (temozolomide)</li> </ul> <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> <li>• Afiya Trust</li> <li>• Black Health Agency</li> <li>• Brainstrust</li> <li>• Brain and Spine Foundation</li> <li>• Brain Tumour UK</li> <li>• British Brain Tumour Association</li> <li>• CANCERactive</li> <li>• Cancer Black Care</li> <li>• Cancer Equality</li> <li>• Cancer 52</li> <li>• Chinese National Healthy Living Centre</li> <li>• Counsel and Care</li> <li>• Equalities National Council</li> <li>• Helen Rollason Heal Cancer Trust</li> <li>• Macmillan Cancer Support</li> <li>• Marie Curie Cancer Care</li> <li>• Muslim Council of Britain</li> <li>• Muslim Health Network</li> </ul>	<p><u>General</u></p> <ul style="list-style-type: none"> <li>• Board of Community Health Councils in Wales</li> <li>• British National Formulary</li> <li>• Care Quality Commission</li> <li>• Commissioning Support Appraisals Service</li> <li>• Department of Health, Social Services and Public Safety for Northern Ireland</li> <li>• Medicines and Healthcare products Regulatory Agency (MHRA)</li> <li>• National Association of Primary Care</li> <li>• NHS Alliance</li> <li>• NHS Commercial Medicines Unit</li> <li>• NHS Confederation</li> <li>• NHS Quality Improvement Scotland</li> <li>• Public Health Wales NHS Trust</li> <li>• Scottish Medicines Consortium</li> </ul> <p><u>Comparator manufacturers</u></p> <ul style="list-style-type: none"> <li>• Cambridge Laboratories (procarbazine)</li> <li>• Hospira (vincristine)</li> <li>• Medac UK (lomustine)</li> <li>• Teva UK (vincristine)</li> </ul> <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> <li>• Brain Tumour Research</li> <li>• British Neurological Research Trust</li> <li>• Department of Neurological Science, University of</li> </ul>

Consultees	Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> <li>• Neurological Alliance</li> <li>• Neurosupport</li> <li>• Samantha Dickson Brain Tumour Trust</li> <li>• South Asian Health Foundation</li> <li>• Specialised Healthcare Alliance</li> <li>• Sue Ryder Care</li> <li>• Tenovus</li> </ul> <p><u>Professional groups</u></p> <ul style="list-style-type: none"> <li>• Association of Cancer Physicians</li> <li>• Association of Surgeons of Great Britain and Ireland</li> <li>• British Association for Services to the Elderly</li> <li>• British Geriatrics Society</li> <li>• British Neuropathological Society</li> <li>• British Oncological Association</li> <li>• British Psychosocial Oncology Society</li> <li>• Cancer Networks Pharmacists Forum</li> <li>• Cancer Research UK</li> <li>• Institute of Neurology</li> <li>• Primary Care Neurology Society</li> <li>• Royal College of Anaesthetists</li> <li>• Royal College of General Practitioners</li> <li>• Royal College of Pathologists</li> <li>• Royal College of Radiologists</li> <li>• Royal Pharmaceutical Society</li> <li>• Royal Society of Medicine</li> <li>• Society of British Neurological Surgeons</li> <li>• United Kingdom Clinical Pharmacy Association</li> </ul>	<p>Liverpool</p> <ul style="list-style-type: none"> <li>• Institute of Cancer Research</li> <li>• MRC Clinical Trials Unit</li> <li>• National Cancer Research Institute</li> <li>• National Institute for Health Research</li> <li>• Policy Research Institute on Ageing and Ethnicity</li> <li>• Research Institute for the Care of Older People</li> </ul> <p><u>Assessment Group</u></p> <ul style="list-style-type: none"> <li>• Assessment Group tbc</li> <li>• National Institute for Health Research Health Technology Assessment</li> </ul> <p><u>Associated Guideline Group</u></p> <ul style="list-style-type: none"> <li>• National Collaborating Centre for Cancer</li> </ul> <p><u>Associated Public Health Groups</u></p> <ul style="list-style-type: none"> <li>• none</li> </ul>

Consultees	Commentators (no right to submit or appeal)
<u>Others</u> <ul style="list-style-type: none"><li>• Department of Health</li><li>• NHS Warrington</li><li>• NHS Westminster</li></ul>	

**GE paper sign-off:** Elisabeth George 24 September 2010.

**Contributors to this paper:**

Information Specialist: Daniel Tuvey  
Technical Lead: Sally Doss  
Technical Adviser: Rebecca Trowman  
Project Manager: Andrew Harding